<DOC>
	<DOCNO>NCT00005778</DOCNO>
	<brief_summary>This study compare effectiveness high-dose cyclophosphamide treatment `` gold standard '' treatment , monthly intravenous ( IV ) cyclophosphamide , people moderate severe lupus respond high-dose corticosteroid therapy . We give patient either IV cyclophosphamide ( 750 milligram per square meter body surface area ) monthly 6 month , follow quarterly maintenance therapy , high-dose IV cyclophosphamide ( 50 milligram per kilogram body weight per day ) first four day study . Patients follow 24 month therapy .</brief_summary>
	<brief_title>High-Dose Intravenous ( IV ) Cyclophosphamide Versus Monthly IV Cyclophosphamide</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE lupus ) remain prototypic autoimmune disease . Recent data show incidence triple since 1970 prevalence 1 800 Rochester , Minnesota . The natural history lupus cohort one ( 1 ) relapsing/ remit ( 2 ) chronic activity , 17 percent patient period long quiescence . Over 75 percent African-American patient 50 percent Caucasian patient renal ( kidney ) involvement . Over 50 percent suffer permanent damage one organ system , 15 percent renal failure . Researchers National Institutes Health ( NIH ) show , patient severe lupus , especially renal involvement , monthly IV pulse cyclophosphamide ( 500 1000 mg/m square BSA ) 6 month follow quarterly maintenance 2 year superior high-dose corticosteroid treatment . NIH others show IV pulse cyclophosphamide also effective severe lupus organ . However , even monthly IV cyclophosphamide successful case , , , associate toxicity , especially premature ovarian failure . For reason , pioneer use high-dose immunoablative cyclophosphamide ( 200 mg/kg ) 10 patient severe lupus refractory treatment . Because initial success approach , include 75 percent complete response ( medication ) renal lupus , conduct control trial high-dose immunoablative cyclophosphamide versus `` gold standard '' monthly IV cyclophosphamide people moderate severe lupus refractory high-dose corticosteroid therapy . We give patient either 750 mg/m2 body surface area IV cyclophosphamide monthly 6 month , follow quarterly maintenance therapy ( readmit patient , necessary , infection complication ) cyclophosphamide 50 mg/kg/d intravenously day 1-4 . We calculate dose cyclophosphamide accord ideal body weight . Patients schedule receive one course therapy . We follow patient accord infective guideline BMT .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>All patient moderatetosevere SLE consider trial , include woman minority . SLE rare disease child feasible include . Patients must meet follow criterion eligible participation clinical trial : Four ACR criterion ( 90 ) , revise Hochberg ( 91 ) classification SLE . Involvement one follow organ system ( renal , neurologic , hematologic , cardiac , pulmonary , cutaneous , gastrointestinal ) moderatetosevere severity indicate `` A '' score BILAG , `` 2 '' `` 3 '' severity SLAM , severe enough require hospitalization organ involvement `` capture '' either BILAG SLAM instrument . A lack response daily corticosteroid moderatetohigh dos ( 0.5 1 mg prednisone/kg/day equivalent antiinflammatory dose methyprednisolone , dexamethasone , triamicinolone ) . When cyclophosphamide accept standard care ( renal neurologic ) , maximally tolerate dose prednisone sufficient meet corticosteroid criterion . The ideal body weight used criterion patient morbidly obese . The equivalent dose triamcinolone ( 4mg triamcinolone=5mg prednisone ) use meet criterion . And/or : A lack response IV pulse corticosteroid ( 1 gram methylprednisolone 180 mg dexamethasone ) . Duration treatment determine lack response 3 day longer neurologic , renal , hematologic , pulmonary , cardiac lupus , one month long serositis . And/or : Equivalent degree immunosuppression azathioprine , methotrexate , cyclosporin , mycophenolate mofetil . Equivalent degree immunosuppression : azathioprine 100 mg daily ; methotrexate 7.5 mg weekly ; cyclosporin 150 mg daily ; mycophenolate mofetil 1000 mg daily . Duration determine lack response one month longer . And/or : Appropriate treatment ( intravenous immunoglobulin hemolytic anemia thrombocytopenia ) . SLE patient seek treatment neurological complaint evaluate neurologist concur patient meet eligibility criterion . Appropriate treatment cutaneous lupus patient may include combination antimalarial drug ( combination hydroxychloroquine chloroquine quinacrine ) . Patients may enter trial receive one dose IV cyclophosphamide `` temporize '' `` stablize '' prior screen visit sign consent previous IV cyclophosphamide PAST organ system , patient present NEW organ system require IV cyclophosphamide . Insurance source fund pay expense relate trial . Exlcusion Criteria : Age le 18 year 70 year . Any risk pregnancy ALL female patient must effective mean birth control infertile due hysterectomy , fallopian tube surgery , menopause . Previous completion NIH IV cyclophosphamide protocol . Cardiac ejection fraction &lt; 45 % . Serum creatinine &gt; 3.0 mg/dL . FVC FEV &lt; 50 % predict . Bilirubin &gt; 2.0 , transaminase &gt; 2x normal . Patients preterminal moribund . SLE patient present arthritis entry organ system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Systemic Lupus Erythematosus ( SLE )</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>High-dose immunoablative therapy</keyword>
</DOC>